PCV157 COST-EFFECTIVENESS OF RIVAROXABAN 2.5 MG BID WITH ASA VERSUS ASA MONOTHERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE OR PERIPHERAL ARTERY DISEASE IN SLOVAKIA
| Autor: | Psota, M., Psenkova, M., Briere, J.B., Bowrin, K., Millier, A., Paulis, L., Krockova, R. |
|---|---|
| Zdroj: | In Value in Health November 2019 22 Supplement 3:S571-S571 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect